publication date: May. 2, 2016

Letter to the Editor GOG Sends Rebuttal Letter to Oncolytics Biotech


The Clinical Cancer Letter received a rebuttal letter for publication from the GOG Foundation and its president, Philip DiSaia, regarding the article “Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response Than Paclitaxel Therapy Alone” which appeared in the March 2016 issue.

The rebuttal was addressed to Brad Thompson, president and CEO of Oncolytics Biotech Inc., relating to a press release issued by the company and an interpretation of the results of the study GOG-0186H, a phase II study evaluating Reolysin plus paclitaxel compared to paclitaxel alone in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer.

The GOG Foundation’s letter follows:


Dear Doctor Thompson,

We have recently become aware of an independent interpretation of the data from GOG-0186H that differed from the interpretation and results presented by David Cohn, M.D. at the recent Society of Gynecologic Oncology (SGO) Annual Meeting on Saturday, March 19, 2016 on behalf of NRG Oncology/The GOG Foundation, Inc. (NRG/GOG). We … Continue reading CCL April – GOG Sends Rebuttal Letter to Oncolytics Biotech

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.